Campbellsville University AstraZeneca PLC Primary Business Activities Paper

User Generated


Business Finance

Campbellsville University


  1. Research and then describe your company's primary business activities. Include:
    1. A brief historical summary,
    2. A list of competitors,
    3. The company's position within the industry,
    4. Recent developments within the company/industry,
    5. Future direction, and
    6. Other items of significance to your corporation.
  2. Include information from a variety of resources. For example:
    1. Consult the Form 10-K filed with the SEC.
    2. Review the Annual Report and especially the Letter to Shareholders
    3. Explore the corporate website.
    4. Select at least two significant news items from recent business periodical.

User generated content is uploaded by users for the purposes of learning and should be used following Studypool's honor code & terms of service.

Explanation & Answer

hello find attached. let me know if you would prefer any editing. goodbye


AstraZeneca PLC Business Activities





AstraZeneca PLC Business Activities
Historical Summary
AstraZeneca was established in 1999 after a union between Astra AB of Sweden and
Zeneca PLC of the United Kingdom. Astra AB was formed in 1913 in Sweden by a corporation
of more than 400 medics and apothecaries who came together to create the company and were
the initial shareholders. The company realized massive developments and towards the
culmination of the First World War, it was recording massive proceeds. On the other hand,
Zeneca Group PLC was formed due to the disintegration of Imperial Chemical Industries (ICI).
ICI was created in 1926 and was one of the oldest and famous companies in the United
Kingdom. By the end of the 1980s, the company faced the challenges of a mature chemical
market, which were marked with high competition, slow growth, and overcapacity in most
regions which led to the restructuring of the company. The company was divided into two groups
in 1993, forming New ICI and ICI bioscience which was referred to as Zeneca. Among the two
Zeneca was the largest with a specialty in pharmaceutical, agrochemical, and specialty products.
Before Astra AB and Zeneca PLC companies merged, Astra AB was a market leader in the
production of different pharmaceutical products and medical devices. On the other hand, Zeneca
PLC was a leading bioscience corporation whose main focus was medicines, farm and field
chemicals, and disease-centered healthcare services (AstraZeneca Pharmaceuticals, 2016).
Currently, AstraZeneca PLC is among the global leader among pharmaceutical
corporations. The business head office is based in London, while its study and growth control
center is located in Sodertalje in Sweden and its industrial facilities distributed in 19 different
nations. The corporation controls nine study centers and development facilities and conducts
transactions in more than one hundred countries across the world. The company majors its



pharmaceutical business in seven different therapeutic fields which include anesthesia and
control of pain, cardiovascular, central nervous system, oncology, infection, respiratory and
gastrointestinal in which it is the global leader. Its main products range from Losec which is
mainly sold in the United States as Prilosec which is the high-selling medicine globally and
Seloken, the top cardioselective beta-blocker in the world. One year after the two companies
merged, the company sales rose to $15.8, with an effective income of $4 billion (AstraZeneca
Pharmaceuticals, 2014).
Competitor Analysis
AstraZeneca PLC was rated number one in the novelty index in 2018 topping the
Pharmaceutical Innovation Index as per IDEA pharma. This was the only period the company
led against its competitors like Johnson & Johnson, Pfizer, Abbot, Novartis, Bayer, Sanofi,
Glaxo Smith Kline, and several others. AstraZeneca was noticeably behind in the development
of cancer immunotherapy drugs, which the industry giants like the Merck, Roche, and BristolMyers were striving to develop but effective experimental examinations carried out by
AstraZeneca gave it a key improvement. The company realized this major milestone after it
launched five new important medications in 2017 mainly in the treatment feilds which could not
be compared with any other company in the industry (AstraZeneca Pharmaceuticals, 2016).
The pharmaceutical industry in the U.S is very competitive. In the last few years, the
market has been very competitive, both in the branded and generic product divisions. The "Big
Pharma" companies compete between themselves and nearly every company is dynamic in R&D
and manufacture of medications in areas with maximum returns like handling of communicable,
psychiatric, and cardiovascular illnesses. In 2019, AstraZeneca was ranked number three with a
5.95% market share. The market leader was Pfizer with 8.52%, Merck came second with 6.11%,

Novartis fourth with 5.1%, and Eli Lilly came fifth with 4.65% (Lloyd, Shimmings and Scrip,
AstraZeneca market share against its competitors in 2018

Source: pharmaintelligence. informa. Com/resources/product-content/pharma-rd-annualreview-2018....

Super useful! Studypool never disappoints.


Related Tags